Literature DB >> 28806348

Radioprotective effect of vitamin E on salivary glands after radioiodine therapy for differentiated thyroid cancer: a randomized-controlled trial.

Arun Upadhyaya1, Pingping Zhou, Zhaowei Meng, Peng Wang, Guizhi Zhang, Qiang Jia, Jian Tan, Xue Li, Tianpeng Hu, Na Liu, Sen Wang, Xiaoxia Liu, Huiying Wang, Chunmei Zhang, Fengxiao Zhao, Ziyu Yan, Xiaoran Wang, Xuemeng Zhang, Wan Zhang.   

Abstract

OBJECTIVES: This study aimed to examine the radioprotective effect of vitamin E on salivary glands after radioactive iodine (I) therapy in patients with differentiated thyroid cancer. PATIENTS AND METHODS: Eighty-two patients with differentiated thyroid cancer were enrolled in this study. They were divided randomly into four groups (control group: 22 cases, group A: 23 cases, group B: 22 cases, and group C: 15 cases) before postsurgical ablation therapy with 100 mCi I. The patients in groups A, B, and C received vitamin E 100, 200, and 300 mg/day orally, respectively, for a duration of 1 week before to 4 weeks after I therapy. Salivary gland function was assessed using salivary gland scintigraphy immediately before and 6 months after I therapy. Uptake fraction (UF), uptake index (UI), excretion fraction (EF), and excretion ratio (ER) of each salivary gland were measured and compared.
RESULTS: On comparison between before and after I therapy in the control group, there was a significant decrease in UF of both right and left parotid glands (all P<0.01). In group A, a significant increase in EF of the right parotid gland (P<0.01) and UI of the right submandibular gland (P<0.05) was found. In group B, there was a significant increase in UI of the right parotid gland and both submandibular glands (all P<0.01). In group C, there was a significant increase in UF of the left parotid gland (P<0.05) and the right submandibular gland (P<0.01). Also, there was a statistical increase in UI in both submandibular glands (all P<0.01). However, on comparing the changes in the post-I therapy salivary scintigraphy parameters among the four groups, there was a significant difference in ΔUI of the right parotid gland (P<0.05) and both submandibular glands (all P<0.01), as well as ΔER of the left parotid gland (P<0.05) and ΔUF of the left submandibular gland (P<0.05).
CONCLUSION: Vitamin E exerts significant protective effects on the parotid and submandibular glands after I therapy.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28806348     DOI: 10.1097/MNM.0000000000000727

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  4 in total

1.  Quantitative Scintigraphy Evaluated the Relationship between 131I Therapy and Salivary Glands Function in DTC Patients: A Retrospective Analysis.

Authors:  Xiaolan Lv; Liang Yin; Weiming Wu; Ning Li; Ruyi Zhang; Xue Li; Qiang Jia; Jian Tan; Peng Wang; Xiangqian Zheng; Xianghui He; Chao Huang; Dihua Li; Yan Wang; Zhaowei Meng
Journal:  J Healthc Eng       Date:  2022-04-14       Impact factor: 3.822

2.  Prevention of salivary gland dysfunction in patients treated with radioiodine for differentiated thyroid cancer: A systematic review of randomized controlled trials.

Authors:  Arunrat Auttara-Atthakorn; Jaruwan Sungmala; Thunyarat Anothaisintawee; Sirimon Reutrakul; Chutintorn Sriphrapradang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-29       Impact factor: 6.055

Review 3.  Sialadenitis as a complication of radioiodine therapy in patients with thyroid cancer: where do we stand?

Authors:  Marios Adramerinas; Dimitrios Andreadis; Konstantinos Vahtsevanos; Athanasios Poulopoulos; Kalliopi Pazaitou-Panayiotou
Journal:  Hormones (Athens)       Date:  2021-06-18       Impact factor: 2.885

4.  Blood prognostic predictors of treatment response for patients with papillary thyroid cancer.

Authors:  Xiangxiang Liu; Zhongke Huang; Xianghui He; Xiangqian Zheng; Qiang Jia; Jian Tan; Yaguang Fan; Cen Lou; Zhaowei Meng
Journal:  Biosci Rep       Date:  2020-10-30       Impact factor: 3.840

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.